« Back to Medicines list

Casodex 50mg Tablets

  • Name:

    Casodex 50mg Tablets

  • Company:
    info
  • Active Ingredients:

    Bicalutamide

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 07/05/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 23/1/2019

Click on this link to Download PDF directly

AstraZeneca Pharmaceuticals (Ireland) DAC

AstraZeneca Pharmaceuticals (Ireland) DAC

Company Products

Medicine NameActive Ingredients
Medicine Name Alvesco 160 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Alvesco 80 micrograms pressurised inhalation,solution Active Ingredients Ciclesonide
Medicine Name Arimidex Active Ingredients Anastrozole
Medicine Name Atacand 8mg 16mg Tablets Active Ingredients Candesartan Cilexetil
Medicine Name Atacand Plus 16/12.5mg Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Medicine Name Bricanyl Turbohaler Active Ingredients Terbutaline sulfate
Medicine Name Brilique 60 mg film-coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg film coated tablets Active Ingredients Ticagrelor
Medicine Name Brilique 90 mg Orodispersible Tablets Active Ingredients Ticagrelor
Medicine Name Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen Active Ingredients Exenatide
Medicine Name Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen Active Ingredients Exenatide
Medicine Name Casodex 50mg Tablets Active Ingredients Bicalutamide
Medicine Name Crestor 5 mg, 10 mg, 20 mg and 40 mg Tablets Active Ingredients Rosuvastatin Calcium
Medicine Name Daxas 250 mcg Film-Coated Tablets Active Ingredients roflumilast
Medicine Name Daxas 500 mcg Film-coated Tablets Active Ingredients roflumilast
Medicine Name Fasenra 30 mg solution for injection in pre filled syringe Active Ingredients Benralizumab
Medicine Name Fasenra 30 mg solution for injection in pre-filled pen Active Ingredients Benralizumab
Medicine Name Faslodex Active Ingredients Fulvestrant
Medicine Name Forxiga 10 mg Film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name Forxiga 5 mg film coated tablets Active Ingredients Dapagliflozin propanediol monohydrate
Medicine Name IMFINZI 50 mg/mL concentrate for solution for infusion Active Ingredients durvalumab
Medicine Name IRESSA 250 mg film-coated tablets Active Ingredients gefitinib
Medicine Name Komboglyze 2.5mg-1000mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Komboglyze 2.5mg-850mg Tablets Active Ingredients Metformin Hydrochloride, Saxagliptin hydrochloride
Medicine Name Losec MUPS 10mg Gastro-resistant Tablets Active Ingredients omeprazole magnesium
1 - 0 of 53 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 7 May 2020 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store or dispose
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 25 April 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 23 January 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 23 January 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 – Marketing Authorisation Holder details updated

Section 8 – Marketing Authorisation numbers updated

Section 10 – date of revision updated

Updated on 5 June 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 - Update with information on the potentiation of coumarin anticoagulant effects which have been reported in patients receiving concomitant Casodex therapy

Section 4.5- Interaction information amended with warfarin and other coumarin anticoagulants when co-administered with Casodex

Section 4.6 - Editorial updates to align with QRD template 

Section 4.6 - Update to the fertility section relating to adequate contraception

Section 4.8 - Update with information on the interaction of coumarin anticoagulants with Casodex

Section 5.3 - Update to preclinical safety data in animal studies

Section 10- Change to the date of revision

Updated on 5 June 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision

Updated on 1 December 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 December 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 LHRH has been unabridged.

Section 4.2 Editorial changes to reflect the QRD template (older to elderly and others)

Section 4.4 Statement on sperm morphology changes & contraception has been added

Section 10 Updated revision date

Updated on 30 November 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 30 November 2016 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 28 May 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2 updated in line with QRD

Section 4.2 updated in line with QRD

Section 4.3 updated in line with QRD

Section 4.4 addition of inforamtion on androgen deprivation therapy may prolong the QT interval

Section 4.5 addition of information on concomitant use of Casdoex with medicinal products knoen to prolong the QT internal or able to induce Torsade de pointes

Section 4.6 updated in line with QRD

Section 4.8 addition of QT prolongation as a ‘not known’ frequency adverse event

Section 4.8 amendment of adverse event reporting details (IMB to HPRA details change)

Section 5.1 updated in line with QRD

Section 5.2 updated in line with QRD

Section 6.6 updated in line with QRD

Section 8 updated in line with QRD

Section 9 updated in line with QRD

Section 10 updated date of revision

Updated on 26 May 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 27 June 2014 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Section 4.8 Add photosensitivity reaction as a rare adverse reaction in the table

- Section 4.8 Add the Reporting of suspected adverse reactions paragraph, email address etc...

- Section 10 New date of revision

Updated on 24 June 2014 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 30 May 2014 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 4 October 2012 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to the SPC in line with the PSUR WS procedure
 
Section 4.8 

Changes to table footnotes.

Updated on 13 September 2011 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 18 April 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8

Include myocardial infarction, correct the frequency descriptor for cardiac failure from uncommon to common.

 

Section 10

Date of revision of text: 11th April 2011

Updated on 14 April 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 30 July 2010 PIL

Reasons for updating

  • Change of contraindications
  • Change to side-effects
  • Change to date of revision

Updated on 29 July 2010 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC changes – Casodex 50mg IR

 

Section 4.3

Text updated in first and second paragraphs, now reads,

 

“Casodex is contraindicated in females and children (see section 4.6).

Casodex must not be given to any patient who has shown a hypersensitivity reaction to the active substance or to any of the excipients of this product.”

 

Section 4.8

Text updated in table, now reads,

 

“Table 1      Frequency of Adverse Reactions

System Organ Class

Frequency

Event

Blood and lymphatic system disorders

Very common

Anaemia

Immune system disorders

Uncommon

Hypersensitivity, angioedema and urticaria

Metabolism and nutrition disorders

Common

Decreased appetite

Psychiatric disorders

Common

Decreased libido
Depression

Nervous system disorders

Very common

Dizziness

 

Common

Somnolence

Cardiac disorders

Uncommon

Cardiac failure4

Vascular disorders

Very common

Hot flush

Respiratory, thoracic and mediastinal disorders

Uncommon

Interstitial lung disease. Fatal outcomes have been reported.

Gastrointestinal disorders

Very common

Abdominal pain
Constipation
Nausea

 

Common

Dyspepsia
Flatulence

Hepato-biliary disorders

Common

Hepatotoxicity, jaundice, hypertransaminasaemia1

 

Rare

Hepatic failure2. Fatal outcomes have been reported.

Skin and subcutaneous tissue disorders

Common

Alopecia
Hirsuitism/hair re-growth
Dry skin
Pruritis
Rash

Renal and urinary disorders

Very common

Haematuria

Reproductive system and breast disorders

Very common

Gynaecomastia and breast tenderness3

 

Common

Erectile dysfunction

General disorders and administration site conditions

Very common

Asthenia
Oedema

 

Common

Chest pain

Investigations

Common

Weight increased

 

1.     Hepatic changes are rarely severe and were frequently transient, resolving or improving with continued therapy or following cessation of therapy.

2.     Hepatic failure has occurred rarely in patients treated with Casodex, but a causal relationship has not been established with certainty. Periodic liver function testing should be considered (see also section 4.4).

3.     May be reduced by concomitant castration.

4.     Observed in a pharmaco-epidemiology study of LHRH agonists and anti-androgens used in the treatment of prostate cancer. The risk appears to be increased when Casodex 50 mg was used in combination with LHRH agonists but no increase in risk was evident when Casodex 150 mg was used as a monotherapy to treat prostate cancer.”

Final paragraph in previous version has been deleted.

Section 9
Now reads as,
“Date of first authorisation:        21 April 2000

Date of last renewal:     21 April 2010”

 

Section 10

Date of revision of text,

”13 July 2010”

 

 

 

Updated on 13 July 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC Changes – Casodex 50mg

 

Section 2

Text changes, now reads,

 

“Each film-coated tablet contains 50 mg of bicalutamide.

Excipients: 61 mg lactose monohydrate per tablet.

For a full list of excipients, see section 6.1.”

 

Section 4.2

Fourth paragraph, the word ‘special’ has been deleted before the word precautions in the final sentence.

 

Section 9

Date of last renewal is now 21 April 2010.

 

Section 10

Date of revision of text is now, 25 June 2010.

 

Updated on 11 February 2010 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to SPC, Casodex 50mg

 

Section 4.4

New Text to 4th paragraph:

 

“Severe hepatic changes and hepatic failure have been observed rarely with Casodex, and fatal outcomes have been reported (see section 4.8 ). Casodex therapy should be discontinued if changes are severe.”

 

Section 4.8

Changes to table:  Changed made in bold text.

 

System Organ Class

Frequency

Event

Blood and lymphatic system disorders

Very common

Anaemia

Immune system disorders

Uncommon

Hypersensitivity reactions (including angioneurotic oedema and urticaria)

Metabolism and nutrition disorders

Common

Anorexia

Psychiatric disorders

Common

Decreased libido
Depression

Nervous system disorders

Very common

Dizziness

 

Common

Somnolence

Vascular disorders

Very common

Hot flush

Respiratory, thoracic and mediastinal disorders

Uncommon

Interstitial lung disease. Fatal outcomes have been reported.

Gastrointestinal disorders

Very common

Abdominal pain
Constipation
Nausea

 

Common

Dyspepsia
Flatulence

Hepato-biliary disorders

Common

Hepatic changes (including elevated levels of transaminases, jaundice)/hepato-biliary disorders1

 

Rare

Hepatic failure2. Fatal outcomes have been reported.

Skin and subcutaneous tissue disorders

Common

Alopecia
Hirsuitism/hair re-growth
Dry skin
Pruritis
Rash

Renal and urinary disorders

Very common

Haematuria

Reproductive system and breast disorders

Very common

Gynaecomastia and breast tenderness3

 

Common

Impotence

General disorders and administration site conditions

Very common

Asthenia
Chest pain
Oedema

 

Common

Chest pain

Investigations

Common

Weight gain

 

 

Section 10

25th January 2010

Updated on 8 February 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 15 September 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to date of revision
  • Change to appearance of the medicine

Updated on 12 August 2009 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.3 Contraindications

Additional last paragraph

“Co-administration of terfenadine, astemizole or cisapride with Casodex is contraindicated (see section 4.5).”

Section 4.4 Special warnings and precautions for use
Major amendments to text, inclusions and deletions.

Section 4.5 Interaction with other medicinal products and other forms of interaction
Major amendments to text, inclusions and deletions.

Section 4.7
Additional wording at end of first paragraph,
”However, it should be noted that occasionally somnolence may occur.  Any affected patients should exercise caution.”

Section 4.8 including Table 1
Major amendments to section.

Section 10
10th March 2009

Updated on 20 February 2007 PIL

Reasons for updating

  • Change to side-effects

Updated on 7 February 2007 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

  • Section 4.3 Removal of text-Each tablet of casodex contains 61mg of lactose.....
  • Section 4.4-Addition of the word hepatic failure in the 4th paragraph of section 4.4
  • Section 4.4-Addition of the text-each tablet of casodex contains...
  • Section 4.8-Addition of text under the subtitle rare-Hepato-billiary disorders-Heaptic failure
  • Section 5.2-Removal of the letter S, in the word micrograms.
  • Section 5.2-Addition of the text-In a clinical study, the mean concentration of...
  • Section 10-change in the date of the revision of the text-to reflect the updated approval date

 

Updated on 17 October 2006 PIL

Reasons for updating

  • Change of active ingredient
  • Change of inactive ingredient
  • Change to warnings or special precautions for use

Updated on 2 October 2006 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 1: Addition of: 50 mg Film-coated Tablets to name of medicinal product

 

Section 2: Addition of: “For excipients, see 6.1.”

 

Section 4.3: Addition of paragraph on galactose intolerance

 

Section 4.8: Deletion of the following sentence: "Casodex in general, has been well tolerated with few withdrawals due to adverse events".

 

Addition of: "Casodex 50 mg is only used in combination with surgical or medical castration.  The reported adverse drug profile of Casodex 50 mg therefore includes effects that may also be seen with castration therapy alone.  The most common reactions reported reflect the pharmacological activity; with the majority (53%) of patients reporting hot flushes and lower proportions (approximately 10%) reporting gynaecomastia or breast tenderness".

 

Deletion of footnote: "May be reduced by concomitant castration". From Frequency of Adverse Reactions table

 

Section 6.1: Addition of 'Monohydrate' after 'Lactose'.

 

Addition of (E171) after Titanium Dioxide

 

Section 6.2: Deletion of “None known” and changed to “Not applicable.”

 

Section 6.6: Change from “no precautions required” to “no requirements”

 

Section 9: Change to date of renewal

Updated on 26 July 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 6 July 2004 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 May 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)